-
Collegium Pharmaceutical (COLL) PT Raised to $58 at Truist Securities
-
Collegium Pharmaceutical issues 2026 financial guidance
-
Collegium Pharma (COLL) Tops Q3 EPS by 37c ; Offers Guidance
-
H.C. Wainwright Assumes Collegium Pharmaceutical (COLL) at Buy
-
Collegium Pharmaceutical (COLL) PT Raised to $45 at Truist Securities
-
Collegium Pharma (COLL) Tops Q2 EPS by 2c ; Offers Guidance
-
Collegium pharmaceutical authorizes $150 million share buyback program
-
Truist Lays Out Prelim Thoughts on Impact to Generic Drugs Amid WH Update on Drug Pricing
-
Collegium Pharma (COLL) Announces $25M Accelerated Share Buyback
-
Avalo Therapuetics (AVTX) Appoints Michael Heffernan as Chairman of the Board
-
H.C. Wainwright Reiterates Buy Rating on Collegium Pharmaceutical (COLL)
-
Collegium Pharma (COLL) Announces Updates to its Board of Directors and Executive Leadership Team
-
Collegium Pharma (COLL) Tops Q4 EPS by 9c, provides guidance
-
Collegium Pharma (COLL) Appoints Nancy S. Lurker to its Board
-
Collegium Pharmaceutical (COLL) PT Lowered to $36 at Piper Sandler
-
Collegium Pharma (COLL) Provides 2025 Financial Guidance and Business Update
-
Collegium Pharmaceutical (COLL) PT Lowered to $40 at Jefferies
-
Collegium Pharma (COLL) Tops Q3 EPS by 4c
-
Collegium Pharma (COLL) Appoints Vikram Karnani as CEO
-
Piper Sandler Reiterates Neutral Rating on Collegium Pharmaceutical (COLL)
-
Collegium Pharmaceutical (COLL) PT Raised to $50 at H.C. Wainwright
-
Collegium Pharmaceutical (COLL) PT Lowered to $37 at Piper Sandler
-
Collegium Pharma (COLL) Misses Q2 EPS by 3c, provides guidance
-
Collegium Pharma (COLL) Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise

